Pulse Biosciences Inc
Gesloten
SectorGezondheidszorg
25.77 5.83
Overzicht
Wijziging aandelenprijs
24u
Min
24.35
Max
26.13
Inkomsten | -1.1M -19M |
|---|---|
Verkoop | 137K 401K |
EPS | -0.241 |
Winstmarge | -4,633.666 |
Werknemers | 116 |
EBITDA | -1.4M -19M |
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +27.21% upside |
Volgende Winsten | 11 aug 2026 |
|---|
Marktkapitalisatie | 179M 1.7B |
|---|---|
Vorige openingsprijs | 19.94 |
Vorige sluitingsprijs | 25.77 |
Nieuwssentiment
By Acuity
34%
66%
94 / 342 Rangschikking in Healthcare
Pulse Biosciences Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
